文献速递血管炎

血管炎领域的新兴细胞疗法

Emerging cell therapies in the vasculitis field.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本文综述了ANCA相关血管炎领域针对自身抗原和免疫细胞亚群的新兴细胞疗法研究进展,重点关注通过双特异性抗体、耐受性脂质体或工程化T细胞选择性清除自身反应性B细胞,以及恢复调节性T细胞功能以延长疾病缓解。

要点

  • ANCA相关血管炎是靶向MPO或PR3自身抗体的系统性自身免疫性小血管炎。
  • 广谱免疫抑制治疗使患者易感染,亟需抗原和细胞特异性疗法。
  • 有前景的方向包括选择性清除自身反应性B细胞和恢复调节性T细胞功能。

核心结论

  • 该领域已具备开始研究新兴细胞疗法的良好条件。

研究设计与样本

  • 本文为综述,检索范围未在摘要中具体报告。

主要发现

  • ANCA相关血管炎患者接受广谱免疫抑制治疗成功,但常使患者易感感染。
  • 研究在理解自身抗原特异性和免疫细胞亚群参与疾病发病机制、复发和缓解方面取得积极进展。
  • 潜在治疗途径包括通过双特异性抗体、耐受性脂质体或工程化T细胞选择性清除自身反应性B细胞。
  • 恢复调节性T细胞功能是延长疾病缓解的有吸引力的途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ANCA vasculitis is a systemic autoimmune small-vessel vasculitis characterized by autoantibodies targeting either MPO or PR3. While patients with ANCA vasculitis are successfully treated with broad-spectrum immunosuppression, these treatments often leave patients vulnerable to infections. Research in the field has made positive gains in regards to understanding autoantigen specificity and immune cell subset involvement in disease pathogenesis, relapse and remission. This review examines the state of the research field as it relates to possible new antigen- and cell-specific therapies in the vasculitis field. Potential avenues of therapeutic interest include selective elimination of autoreactive B cells by bispecific antibodies, tolerogenic liposomes or engineered T cells. Additionally, restoration of regulatory T-cell function is an attractive avenue to prolong remission of disease. Collectively, the field is well poised to begin investigating new and emerging cell therapies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Free ME. Emerging cell therapies in the vasculitis field. Rheumatology (Oxford). 2025. PMID: 40071405. doi:10.1093/rheumatology/keae518

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。